A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples